

Supplementary Materials

Figure S1. Assessment of Dose Proportionality for Plasma NHC (A) AUC₀₋₁₂ and (B) C_{max} on Day 11 Following Administration of Multiple Oral Doses of Molnupiravir Every 12 Hours for 10.5 Days to Healthy Participants (n = 6 for 400 mg, n = 6 for 600 mg, n = 12 for 800 mg)

 \mathbf{A}







CI, confidence interval; NHC, β -D-N4-hydroxycytidine

A true slope of 1.0 indicates perfect dose proportionality. Least-squares estimate and confidence interval from linear mixed-effects model including ln-dose as a continuous effect, performed on natural log-transformed values.